What Is PFE Fair Value?
Pfizer Inc. (PFE) fair value estimate using multiple valuation models, updated daily.
As of September 16, 2026, Pfizer Inc. (PFE) has a composite fair value estimate of $43.52 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $27.46, suggesting the stock is undervalued by 58.5%.
Data as of September 16, 2026 (today)
Composite Fair Value
Undervalued4 of 4 models$43.52
vs. current price of $27.46(+58.5%)
How Is PFE Fair Value Calculated?
Four independent models estimate what PFE is worth. Each uses different inputs and assumptions. The composite blends them by weight.
PFE Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$52.99
+93.0%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$42.33
+54.2%Undervalued
Inputs used
PFE Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$31.63
+15.2%Undervalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$29.75
+8.3%Fair Value
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $27.46 is 93.0% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $12.74B | $12.07B |
| Year 2 | $12.99B | $11.67B |
| Year 3 | $13.25B | $11.28B |
| Year 4 | $13.51B | $10.90B |
| Year 5 | $13.79B | $10.54B |
| Year 6 | $14.06B | $10.19B |
| Year 7 | $14.34B | $9.85B |
| Year 8 | $14.63B | $9.52B |
| Year 9 | $14.92B | $9.21B |
| Year 10 | $15.22B | $8.90B |
| Terminal Value | $518.07B | $302.97B |
What Are PFE's Key Financial Metrics?
Earnings & Growth
Current Price
$27.46
EPS (TTM)
$0.76
Forward P/E
9.5
Profit Margin
6.8%
Cash & Balance Sheet
Free Cash Flow
12.5B
EBITDA
25.4B
Book Value
$14.95
Total Debt
63.5B
What Do Analysts Say About PFE?
Low
$25.00
Average
$28.88
High
$35.75
Upside
+5.2%
PFE Fair Value FAQ
What is the fair value of PFE?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), PFE's estimated fair value is $43.52. The stock is currently trading at $27.46, which makes it undervalued by our analysis.
How is PFE's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is PFE overvalued or undervalued?
Based on our analysis, PFE is undervalued. The current price of $27.46 is 58.5% below our estimated fair value of $43.52.
What do Wall Street analysts say about PFE?
26 analysts cover Pfizer Inc. with a consensus rating of "Buy." The average price target is $28.88, ranging from $25.00 to $35.75. This implies 5.2% upside from the current price.